CLINICAL TRIALS PROFILE FOR PERIOGARD

All Clinical Trials for Periogard

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01902446 ↗	Prehospital Ventilator-Associated Pneumonia Prevention Trial	Completed	Nicholas M Mohr		2013-07-01	Traumatic injury in rural America is a significant cause of morbidity and mortality, and the challenges of a rural trauma system can put patients at unique risk. Prolonged transport times to a trauma center, stopping for care at referring hospitals, and longer exposure to care-associated factors distinguish rural patients from their urban counterparts. Ventilator-associated pneumonia (VAP) is a significant risk in rural patients, increasing hospital stay, healthcare costs, and even mortality in the critically injured. The investigators propose a pilot study to test the hypothesis that a single dose of oral chlorhexidine gluconate (antiseptic) for trauma patients in the prehospital environment will decrease subsequent development of early VAP. Chlorhexidine is currently a standard therapy in intensive care units to prevent airway colonization and subsequent development of VAP. Demonstrating safety and effectiveness of prehospital infection control practices could significantly improve outcomes of traumatic injury in rural America.
NCT01902446 ↗	Prehospital Ventilator-Associated Pneumonia Prevention Trial	Completed	University of Iowa		2013-07-01	Traumatic injury in rural America is a significant cause of morbidity and mortality, and the challenges of a rural trauma system can put patients at unique risk. Prolonged transport times to a trauma center, stopping for care at referring hospitals, and longer exposure to care-associated factors distinguish rural patients from their urban counterparts. Ventilator-associated pneumonia (VAP) is a significant risk in rural patients, increasing hospital stay, healthcare costs, and even mortality in the critically injured. The investigators propose a pilot study to test the hypothesis that a single dose of oral chlorhexidine gluconate (antiseptic) for trauma patients in the prehospital environment will decrease subsequent development of early VAP. Chlorhexidine is currently a standard therapy in intensive care units to prevent airway colonization and subsequent development of VAP. Demonstrating safety and effectiveness of prehospital infection control practices could significantly improve outcomes of traumatic injury in rural America.
NCT02589067 ↗	Decolonization of the Oropharynx, an Important and Neglected Reservoir of S. Aureus Colonization	Completed	Thrasher Research Fund	Phase 2	2015-10-01	The problem of interest is the high rate of recurrent SSTIs in children caused by S. aureus despite the use of systemic antibiotic treatment, due to difficulties in decolonization and the prevalence of antibiotic-resistant strains such as MRSA. This problem will be studied through a randomized, double-blind, placebo-controlled clinical trial of the use of a 0.12% clorhexidine gluconate (CHG) oral rinse in decolonizing S. aureus in the oropharynx in children 5-17 years old. CHG is an excellent candidate for use in children as its safety has been widely established, and it is readily commercially available. Eligible, consented subjects will be asked to participate in a baseline study visit in which swabs of their oropharynx and nares are obtained, and they are educated on the use of either CHG oral rinse or a placebo oral rinse containing saline. The subjects will be instructed to perform the oral rinse twice daily for seven days. Two follow-up visits will occur at 7 and 28 days post-baseline, where subjects' nares and oropharynx are again swabbed in order to ascertain short- and long-term decolonization of S. aureus. This procedure will serve to 1) determine the efficacy of a CHG oral rinse in decolonization of S. aureus, 2) investigate the safety, tolerability, and compliance of oropharyngeal decolonization among children and their caregivers, and 3) determine the genetic backgrounds of strains of S. aureus associated with continued colonization.
NCT02589067 ↗	Decolonization of the Oropharynx, an Important and Neglected Reservoir of S. Aureus Colonization	Completed	Los Angeles Biomedical Research Institute	Phase 2	2015-10-01	The problem of interest is the high rate of recurrent SSTIs in children caused by S. aureus despite the use of systemic antibiotic treatment, due to difficulties in decolonization and the prevalence of antibiotic-resistant strains such as MRSA. This problem will be studied through a randomized, double-blind, placebo-controlled clinical trial of the use of a 0.12% clorhexidine gluconate (CHG) oral rinse in decolonizing S. aureus in the oropharynx in children 5-17 years old. CHG is an excellent candidate for use in children as its safety has been widely established, and it is readily commercially available. Eligible, consented subjects will be asked to participate in a baseline study visit in which swabs of their oropharynx and nares are obtained, and they are educated on the use of either CHG oral rinse or a placebo oral rinse containing saline. The subjects will be instructed to perform the oral rinse twice daily for seven days. Two follow-up visits will occur at 7 and 28 days post-baseline, where subjects' nares and oropharynx are again swabbed in order to ascertain short- and long-term decolonization of S. aureus. This procedure will serve to 1) determine the efficacy of a CHG oral rinse in decolonization of S. aureus, 2) investigate the safety, tolerability, and compliance of oropharyngeal decolonization among children and their caregivers, and 3) determine the genetic backgrounds of strains of S. aureus associated with continued colonization.

Clinical Trial Conditions for Periogard

Condition Name

Condition Name for Periogard
Intervention	Trials
Dental Plaque	2
Gingivitis	2
Aggressive Periodontitis	1
Coronavirus Infection	1

Condition MeSH

Condition MeSH for Periogard
Intervention	Trials
Gingivitis	2
Dental Plaque	2
Infections	1
Pneumonia	1

Clinical Trial Locations for Periogard

Trials by Country

Trials by Country for Periogard
Location	Trials
United States	3
Brazil	3
Thailand	1

Trials by US State

Trials by US State for Periogard
Location	Trials
California	1
Iowa	1
North Carolina	1

Clinical Trial Progress for Periogard

Clinical Trial Phase

Clinical Trial Phase for Periogard
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	1
Phase 3	1

Clinical Trial Status

Clinical Trial Status for Periogard
Clinical Trial Phase	Trials
Completed	5
ACTIVE_NOT_RECRUITING	1
Terminated	1

Clinical Trial Sponsors for Periogard

Sponsor Name

Sponsor Name for Periogard
Sponsor	Trials
Colgate Palmolive	2
Nicholas M Mohr	1
University of North Carolina, Chapel Hill	1

Sponsor Type

Sponsor Type for Periogard
Sponsor	Trials
Other	11
Industry	2

Periogard (chlorhexidine gluconate) — Clinical Trials Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is Periogard and how is it used?

Periogard is a brand of chlorhexidine gluconate (CHG) indicated for reduction in plaque and gingivitis in adults, used as an antiseptic oral rinse. It is positioned as a locally acting antimicrobial to support periodontal disease management and oral hygiene.

Core product attributes relevant to market performance

• Route: oral rinse (topical, not systemic)
• Active ingredient: chlorhexidine gluconate
• Therapeutic intent: plaque/gingivitis reduction through antimicrobial action
• Regulatory category: established OTC and prescription-available CHG rinse ecosystem across multiple markets (exact category varies by country)

What is the clinical trials update for Periogard?

A clean Periogard-only clinical trials pipeline update is not retrievable from the available record set as a consolidated, date-stamped program (Periogard-specific NCT listings and sponsor-controlled updates are not available in the provided information). This analysis therefore treats Periogard as a branded CHG rinse and focuses on what can be evidenced at the class level rather than presenting unverifiable “Periogard-only” trial claims.

Evidence-based position

• The clinical footprint for chlorhexidine mouthrinses is mature, with the bulk of efficacy evidence established through older randomized controlled trials and post-marketing use patterns.
• Current trial activity, where reported, is typically in comparative formulations (timed-release CHG variants, alternative antiseptics, or adjunct periodontal regimens) rather than brand-new Periogard-centric registration programs.

Implication for investors and R&D

• Near-term Periogard growth is unlikely to hinge on new pivotal endpoints unless a specific regulator-facing program exists for the brand. Most value uplift typically comes from market access, channel expansion, and formulation optimization rather than brand-new clinical differentiation.

Is there an active Periogard development pipeline?

No Periogard-specific, sponsor-attributed, near-term development milestones are present in the provided material that would support a credible “pipeline update” with dates, phases, or endpoints.

What does the periogard market landscape look like?

Chlorhexidine gluconate mouthrinses operate in a competitive oral antiseptic environment. Key competitive dynamics include:

• Generic CHG rinses (pricing pressure)
• Alternative antiseptics (e.g., essential-oil rinses, CPC-based products in some segments, and adjunct periodontal therapies)
• Dental clinic and pharmacy channel influence (dentists drive adoption in gingivitis and preventive care; pharmacy supports compliance and repeat purchases)
• Regulatory and labeling: indications and warnings affect adoption in local markets

Competitive set (category-level)

Because Periogard-specific share data is not supplied, the competitive analysis is framed at the active-ingredient and channel level:

1. Generic chlorhexidine gluconate rinses
   • Direct substitution
   • Often lower price than branded products
2. Premium/novel oral antiseptic lines
   • Positioned as longer-lasting, lower staining, or improved taste
3. Adjunct periodontal devices and regimens
   • Toothpaste systems, flossers, professional scaling programs that influence routine use

How should Periogard be valued in a market projection framework?

Periogard’s market trajectory should be modeled on:

• Stable demand for antiseptic rinses in preventive dental care
• Catastrophic erosion risk if a market loses differentiation or faces aggressive generic pricing
• Adoption stickiness driven by clinician recommendation and established user behavior
• Regulatory continuity: as a mature active, it typically faces fewer clinical uncertainty risks than early-stage therapeutics

Projection drivers

• Price/mix: branded premium vs generic substitution
• Channel: pharmacy repeat vs dentist-influenced initial adoption
• Usage frequency: driven by dental seasonality and guideline adherence
• Safety/tolerability perceptions: staining, taste alteration, and irritation expectations influence compliance

Scenario framework (brand-level)

With no Periogard-specific share/volume inputs provided, projections should be expressed as scenario bands tied to category-level maturity rather than exact point forecasts.

Base case (mature market)

• Demand is flat to low single-digit growth driven by population-level oral care spending and steady adherence.
• Brand share gradually compresses versus generics, with growth coming from incremental users and periodic clinician re-engagement.

Downside case (accelerated generic substitution)

• Branded pricing pressure increases.
• Loss of retailer shelf economics reduces distribution footprint and repeat rates.

Upside case (differentiation via formulation/channel)

• Improved tolerability or redesigned packaging increases compliance and repeat.
• Expanded distribution (dentist offices, dental service orgs, and regional pharmacy chains) stabilizes brand share.

What does Periogard’s commercial outlook imply for near-term investment decisions?

Given CHG mouthrinses are mature, the credible levers for value creation typically sit in:

• Commercial execution: distribution and physician/dentist call programs
• Portfolio defense: maintaining branded shelf position against generics
• Product iteration: tolerability improvements and localized labeling strategies
• Compliance design: dosing instructions and patient-facing education to reduce discontinuation from irritation/staining concerns

What are the key risks to Periogard market performance?

1. Generic substitution
   • The strongest persistent headwind for branded CHG rinse pricing and volume
2. Tolerability and staining
   • CHG is associated with tooth staining and taste alteration in some users, which can reduce repeat adherence
3. Channel concentration
   • Over-reliance on a single channel (clinic vs retail) increases volatility
4. Regulatory/labeling variance
   • Indication wording and permitted claims differ by region and can shift demand

Key Takeaways

• Periogard is an established chlorhexidine gluconate oral rinse used for plaque and gingivitis reduction in a mature antiseptic category.
• A Periogard-only clinical trials update cannot be supported by date-stamped, sponsor-specific pipeline evidence in the provided record set; CHG clinical evidence is mature and current activity is typically comparative rather than Periogard registration-driven.
• Market growth is driven more by commercial execution and channel dynamics than by clinical novelty.
• Projection should be modeled in scenario bands: base case is steady-to-low growth with ongoing branded share pressure from generics; upside requires formulation/channel differentiation; downside follows accelerated pricing and distribution erosion.
• The primary risks are generic substitution, tolerability-driven discontinuation, channel dependence, and labeling/regulatory variance.

FAQs

1. Is Periogard still clinically supported by modern evidence?
Yes, chlorhexidine mouthrinses have a long clinical evidence base for plaque and gingivitis reduction, but Periogard-specific, new pivotal trials are not evidenced in the provided record set.

2. What is the biggest driver of Periogard demand in practice?
Clinician recommendation and established patient routine use, moderated by tolerability and staining perceptions that affect repeat compliance.

3. How do generics typically affect Periogard pricing and sales?
They compress branded pricing power and can reduce volume over time unless the brand maintains strong distribution economics and adherence support.

4. What product attributes most influence patient adherence?
Perceived taste, mouth irritation, and staining risk, which directly affect discontinuation and repeat purchase behavior.

5. What levers can create upside for Periogard without new pivotal trials?
Channel expansion, improved tolerability/formulation strategy, and patient-facing education that supports consistent dosing and reduces early discontinuation.

---

References

[1] FDA. Chlorhexidine gluconate (CHG) drug and safety information. U.S. Food and Drug Administration.
[2] European Medicines Agency (EMA). Public assessment information for chlorhexidine-containing medicinal products. European Medicines Agency.
[3] PubChem. Chlorhexidine gluconate. National Center for Biotechnology Information.
[4] ClinicalTrials.gov. Chlorhexidine gluconate mouthrinse listings and study records. U.S. National Library of Medicine.
[5] WHO. Oral health fact sheets and prevention guidance relevant to gingivitis and plaque control. World Health Organization.